Alkermes
leveraging alkermes molecular design capabilities to target dysfunction in narcolepsy in complex with peptide agonist working to develop a best in class molecule designed to mimic potency and performance of endogenous peptide agonist with orally therapy possess favorable half life have profile that mirrors natural wake cycle avoid safety risks associated with stimulant medications pharmacodynamic figure adapted from hong nature communications | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
135 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Investor Presentation
June 2023
leveraging alkermes molecular design capabilities to target dysfunction | Alkermes
Investor Presentation
March 2023
leveraging alkermes molecular design capabilities to target dysfunction | Alkermes
Investor Presentation
January 2023
leveraging alkermes molecular design capabilities to target dysfunction | Alkermes
Investor Conference
January 2022
receptor agonist | Alkermes
Related slides by other companies
Vigil Neuroscience
IPO
January 2022
novel small molecule agonist program vigil | Vigil Neuroscience
Vigil Neuroscience
IPO
January 2022
small molecule agonist program summary vigil | Vigil Neuroscience
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io